The Latest Breaking News from BMO Capital

BMO Capital analyst Ray Kwan raised the price target for Baytex Energy Corp (TSX:BTE) (OTC:BTEGF) to C$8.50 from C$8 while maintaining the Market Perform rating on the shares. The analyst mentions that while the quarter was in line, the Clearwater at Peavine continues to deliver exceptional results, with recent wells having initial rates as high…

Advantage Energy Ltd (TSX: AAV) (OTC: AAVVF) price target has been raised to C$14 from C$12 by BMO Capital analyst Mike Murphy.

BMO Capital analyst Rene Cartier raised the price target for Altius Minerals Corp  (TSX:ALS) (OTC:ATUSF) to C$23 from C$22 while maintaining the Market Perform rating on the shares. The target price was increased as the analyst raised multiples to align more closely with royalty/streaming peers. The analyst states that ALS delivered slightly better-than-expected 1Q22 attributable…

BMO Capital analyst Ryan Thompson lowered the price target on First Majestic Silver Corp (TSX:FR) NYSE: AG) to C$12 from C$13 while maintaining the Market Perform rating on the shares. First Majestic is an intermediate primary silver producer with three operating mines in Mexico. The analyst states that the consolidated Q1 gold and silver production…

BMO Capital cut Bank of America Corporation (NYSE: BAC) price target from $48 to $46. Bank of America shares rose 0.3% to $38.95 in pre-market trading.

Upgrades

BMO Capital analyst Andrew Strelzik downgraded Wendy's Co (NASDAQ:WEN) to Market Perform from Outperform with a reduced price target of $22, down from $28, implying a 5.31% upside. The analyst believes the company is less well-positioned to handle a tighter U.S. consumer spending environment than its peers against rising pressures on discretionary spending. Thus, Strelzik…

BMO Capital has decided to maintain its Market Perform rating of IBM (NYSE:IBM) and lower its price target from $155.00 to $148.00. Shares of IBM are trading down 0.04% over the last 24 hours, at $125.93 per share.

BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00. Shares of C4 Therapeutics are trading down 20.49% over the last 24 hours, at $9.00 per share.